ProKidney Corp. Total Liabilities
ProKidney Corp. total liabilities. Based on the latest financial reports, ProKidney Corp. (PROK) has total liabilities worth $26.18 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of ProKidney Corp. to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ProKidney Corp. (2019–2025)
Total liabilities of ProKidney Corp. from 2019 to 2025. This chart illustrates how ProKidney Corp.'s total liabilities have evolved over time, based on quarterly financial data.
ProKidney Corp. Competitors by Total Liabilities
The table below lists competitors of ProKidney Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Lanfeng Bio-chemical Co Ltd
SHE:002513
|
China | CN¥3.80 Billion |
|
Hi-Lai Foods Co Ltd
TWO:1268
|
Taiwan | NT$5.10 Billion |
|
Eagle Point Income Company Inc
NYSE:EIC
|
USA | $169.02 Million |
|
Summarecon Agung Tbk
JK:SMRA
|
Indonesia | Rp23.49 Trillion |
|
Lewis Group Limited
JSE:LEW
|
South Africa | ZAC3.67 Billion |
|
Shanghai Xintonglian Packaging Co Ltd
SHG:603022
|
China | CN¥346.54 Million |
|
Nam Kim Steel JSC
VN:NKG
|
Vietnam | ₫8.39 Trillion |
Liability Composition Analysis (2019–2025)
This chart breaks down ProKidney Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of ProKidney Corp..
Liquidity & Leverage Metrics
ProKidney Corp. Total Liabilities Ratios Explained
ProKidney Corp. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProKidney Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProKidney Corp. (2019–2025)
The table below shows the annual total liabilities of ProKidney Corp. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.78 Million | -11.80% |
| 2024-12-31 | $39.44 Million | +34.98% |
| 2023-12-31 | $29.22 Million | +123.76% |
| 2022-12-31 | $13.06 Million | -2.42% |
| 2021-12-31 | $13.38 Million | +95.74% |
| 2020-12-31 | $6.84 Million | +83.57% |
| 2019-12-31 | $3.72 Million | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more